Tyrosine kinase inhibitors (TKI) are effective target-specific inhibitors of the constitutively active BCR::ABL1 oncoprotein characterizing chronic myeloid leukemia (CML). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.